ホーム › びまん性大細胞型B細胞リンパ腫 › テネシー
テネシーにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
テネシー内の拠点で、びまん性大細胞型B細胞リンパ腫に関する18件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Tennessee Cancer Specialists ( Site 7004), Knoxville
- SCRI Oncology Partners ( Site 7002), Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Tennessee Cancer Specialists ( Site 7000), Knoxville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- The University of Tennessee Medical Center ( Site 0142), Knoxville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Vanderbilt University Medical Center, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。